# Crispr Therapeutics AG (CRSP)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $4.52B  
**Price:** $50.23 (+1.60%)

> CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing-based medicines for serious diseases. The company develops therapies using its proprietary CRISPR/Cas9 platform, which enables precise changes to DNA and supports a portfolio of programs across hemoglobin disorders, oncology, regenerative medicine, rare diseases, and autoimmune-related research areas. Its current product set includes approved and investigational cell and gene therapies designed to address conditions with significant unmet medical needs, while its research pipeline spans both ex vivo and in vivo approaches. CRISPR Therapeutics AG also works with strategic partners in biotech and life sciences to advance development and commercialization activities. Headquartered in Zug, Switzerland, the company plays a notable role in the evolving market for gene editing, where its technologies are used to create targeted, next-generation therapeutic candidates.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $4M | — | -$665M | -$582M | — |
| 2024 | $37M | — | -$467M | -$366M | — |
| 2023 | $371M | — | -$223M | -$154M | — |
| 2022 | $1M | — | -$673M | -$650M | — |
| 2021 | $915M | — | $374M | $378M | — |
| 2020 | $719,000 | — | -$354M | -$349M | — |
| 2019 | $290M | — | $47M | $67M | — |
| 2018 | $3M | — | -$159M | -$165M | — |
| 2017 | $41M | — | -$65M | -$68M | — |
| 2016 | $5M | — | -$68M | -$23M | — |
| 2015 | $247,000 | — | -$26M | -$26M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $2.27B | $343M | $1.92B | $348M | — |
| 2024 | $2.24B | $310M | $1.93B | $298M | — |
| 2023 | $2.23B | $347M | $1.88B | $389M | — |
| 2022 | $2.24B | $368M | $1.88B | $212M | — |
| 2021 | $2.75B | $352M | $2.40B | $923M | — |
| 2020 | $1.83B | $164M | $1.66B | $1.17B | — |
| 2019 | $1.07B | $127M | $939M | $944M | — |
| 2018 | $489M | $97M | $392M | $457M | — |
| 2017 | $271M | $84M | $188M | $240M | — |
| 2016 | $345M | $112M | $233M | $316M | — |
| 2015 | $159M | $124M | -$29M | $156M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$345M | $914,000 | -$346M |
| 2024 | -$143M | $2M | -$145M |
| 2023 | -$260M | $9M | -$270M |
| 2022 | -$496M | $37M | -$533M |
| 2021 | $539M | $82M | $457M |
| 2020 | -$238M | $18M | -$257M |
| 2019 | $57M | $7M | $50M |
| 2018 | -$96M | $3M | -$99M |
| 2017 | -$70M | $8M | -$78M |
| 2016 | -$53M | $3M | -$56M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CRSP)